David Morrissey

David Morrissey has more than 25 years of experience in molecular and cellular biology, with a focus on nucleic acid and gene editing based therapeutic approaches. Prior to joining Triplet Therapeutics, Inc., he was Senior Vice President at Intellia Therapeutics, responsible for CRISPR/Cas9 gene editing platform development for therapeutic applications as well as delivery technology for in vivo and ex vivo therapeutic programs. Prior to Intellia, David was Executive Director at the Novartis Institutes for Biomedical Research, where he headed its RNAi Therapeutics Unit and the development of proprietary RNA chemistries and delivery formulations for therapeutic programs. As the Senior Director of Antiviral Therapeutics at Sirna Therapeutics, he led teams for the development of siRNA therapeutics to treat HCV and HBV infection. David has been issued a number of U.S. patents, and authored key publications in the RNA and gene editing fields. He received his Ph.D. in developmental biology from Wesleyan University and completed his postdoctoral fellowship in oncology at Bristol-Myers Squibb.